Tag Archive | "Alexion"

Alexion to buy Synageva Biopharma

Tags: ,


Alexion Pharmaceuticals have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. Read the full story

Partnering Agreements with Alexion Pharmaceuticals

Tags: ,


The Partnering Agreements with Alexion Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. Read the full story

Partnering with Alexion Pharmaceuticals: Compassionately developing for ultra rare diseases

Tags: , ,


Alexion Pharmaceuticals is a global biopharmaceutical company developing and delivering medications for ultra rare diseases. Read the full story

M&A activity – Alexion Pharmaceuticals

Tags: , ,


Alexion Pharmaceuticals has announced only 2 M&A deals since 2009, with the lead deals being the acquisition of Enobia Pharma and Taligen Therapeutics. Read the full story

Prothelia and Alexion form a pharma alliance

Tags: , , ,


Prothelia and University of Nevada have entered into strategic pharma alliance agreements with Alexion for the development of Laminin-111. Read the full story

Roche seeking for potential Alexion bid: Biotech Rumor mill

Tags: , , , ,


Biotech Rumor mill: Alexion Pharmaceuticals , the big biotech company, whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs Group Inc. as an adviser as it prepares for a possible takeover offer from Roche Holding AG (ROG), said people with knowledge of the matter Read the full story

Alexion biotech deals Ensemble Therapeutics for ultra-rare disorder treatments

Tags: , , ,


Alexion, a big biotech company, has entered biotech deals with Ensemble Therapeutics to find treatments for ultra-rare disorders. Read the full story

Biotech rumor mill: Alexion valuation could choke any Roche bid

Tags: , , ,


Buying Alexion Pharmaceuticals would help Roche make a splash in the newly lucrative area of rare or so-called orphan diseases, but it could command a price that the Swiss drugmaker is ultimately not willing to pay, according to the biotech rumor mill.

Read the full story

Alexion Pharmaceuticals

Tags: ,


Return to top 50 biotech list

Summary

Website: Alexion Pharmaceuticals

Headquarters: Cheshire, USA

Ticker Symbol: ALXN(NASDAQ)

SEC Link: Alexion Pharmaceuticals

Subsidiaries:

Enobia Pharma

Taligen Therapeutics

Top 50 biotech ranking*: 16

*Ranking based on reported global pharma sales for year ending December 2011.

Sales revenue (USD billions): $1.134

Alexion Revenues

 

 

 

 

 

 

 

 

 

 

 

R&D spend (USD millions): $223

Alexion R&D

 

 

 

 

 

 

 

 

 

 

Partnering Activity

View partnering activity: 2013 | 2012 | 2011 | 2010 2009 | 2008 | 2007 | 2006

Full details can be found at CurrentAgreements (subscription required)

M&A Activity

View M&A activity: 2013 | 2012 2011 | 20102009 | 2008 | 2007 | 2006

Full details can be found at CurrentAgreements (subscription required)

Available reports from Current Partnering:

Partnering Agreements with Alexion Pharmaceuticals 2005-2013

Partnering Deals and Alliances with Big Biotech 

Bigbiotech Partnering Yearbook 2013

Search all reports

Available resources providing deal coverage for Alexion Pharmaceuticals:

CurrentAgreements (subscription required)

Try a one month subscription

Search Current Partnering for mention of Alexion Pharmaceuticals:

Search now

Return to top 50 biotech list

Alexion to stabilise financing through $400 million share repurchase

Tags: , ,


Alexion Pharmaceuticals topped the financing news section with its announcement to commence a repurchase program of its common stock worth up to $ 400 million. This announcement was authorized by the Company’s Board of Directors Read the full story